Price Target Update on Pernix Therapeutics Holdings (NASDAQ:PTX)

Pernix Therapeutics Holdings (NASDAQ:PTX) : The highest short term price target forecast on Pernix Therapeutics Holdings (NASDAQ:PTX) is $10 and the lowest target price is $3. A total of 2 equity analysts are currently covering the company. The average price of all the analysts is $6.5 with a standard deviation of $4.95.

Other Equity analysts have also commented on the company shares. Brokerage firm Oppenheimer downgrades its rating on Pernix Therapeutics Holdings (NASDAQ:PTX). The shares have been rated Perform. Previously, the analysts had a Outperform rating on the shares. The rating by the firm was issued on March 17, 2016.

Pernix Therapeutics Holdings (NASDAQ:PTX): stock turned positive on Thursday. Though the stock opened at $0.485, the bulls momentum made the stock top out at $0.52 level for the day. The stock recorded a low of $0.47 and closed the trading day at $0.5087, in the green by 5.89%. The total traded volume for the day was 5,665,115. The stock had closed at $0.4804 in the previous days trading.

The company shares have dropped -91.01% from its 1 Year high price. On Jul 17, 2015, the shares registered one year high at $6.44 and the one year low was seen on May 24, 2016. The 50-Day Moving Average price is $0.50 and the 200 Day Moving Average price is recorded at $1.52. On the companys insider trading activities, Siegel Barry J, officer (Senior VP and General Counsel) of Pernix Therapeutics Holdings, Inc. had purchased 5,000 shares on August 19, 2015 in a transaction. The price per share was $4.49 and the total amount of the disclosed transaction was $22,450.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

Pernix Therapeutics Holdings, Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition, development and commercialization of prescription drugs, primarily for the United States market. The Company focuses on underserved therapeutic areas, such as central nervous system (CNS), including neurology and psychiatry, as well as other specialty therapeutic areas. The Companys products include Treximet, an analgesic indicated for acute migraine; Silenor (doxepin), a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance, and Khedezla (desvenlafaxine extended-release tablets), for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries, Macoven Pharmaceuticals, LLC (Macoven) and Cypress Pharmaceuticals, Inc. (Cypress).

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.